PMID: 7032682Jan 15, 1982Paper

Antibody-dependent cell-mediated cytotoxicity in human cancer: characterization of patient leukocyte activity and treatment effects

Cancer
E M HershD Stewart

Abstract

Antibody-dependent cell-mediated cytotoxicity (ADCC), medicated by peripheral blood Hypaque-Ficoll separated mononuclear cells, was studied in humans using chicken erythrocytes (CRBC) incubated in a 1:1200 dilution of rabbit anti-CRBC and human B erythrocytes (HRBC) incubation in a 1:20 dilution of isoantibody. At the optimal target effector ratio of 3:1, ADCC to both CRBC and HRBC was significantly higher than normal in 27 lung cancer, 18 malignant melanoma, and seven colon cancer patients, but not in 20 breast cancer patients. Chemotherapy (single-agent or combination) in 12 patients did not effect ADCC in vitro but significantly suppressed ADCC to both targets after only four or five days of therapy in vivo (ADCC to CRBC, 47.4 to 24.1% lysis: ADCC to HRBC, 48.1 to 16.3% lysis). Immunotherapy with intravenous (IV) corynebacterium parvum or IV methanol extraction residue of BCG (MER) boosted ADCC to both targets within four to seven days of the first dose. It was found that ADCC to HRBC but not to CRBC was completely absent in three cases of active hairy cell leukemia but was present in two cases in remission. The ADCC to HRBC showed an age-dependent increase in both the 51 normal subject and the cancer patients. This was not ...Continue Reading

References

Jul 1, 1977·Cancer·P PerlmannG R Pape
Apr 1, 1978·Journal of the National Cancer Institute·W V HahnL H Hatlen
Jul 1, 1978·International Journal of Radiation Oncology, Biology, Physics·S O AsbellL W Brady
Feb 1, 1978·The Journal of Experimental Medicine·R L EvansS F Schlossman
May 1, 1977·International Journal of Radiation Oncology, Biology, Physics·J P ConcannonJ Conway
Dec 1, 1978·The Journal of Clinical Investigation·G M ShawA F LoBuglio
Feb 1, 1976·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MantovaniF Spreafico
Jan 1, 1975·Clinical Immunology and Immunopathology·R P GaleJ L Fahey
Aug 1, 1974·The Journal of Clinical Investigation·E M HershE J Freireich
Jan 25, 1973·The New England Journal of Medicine·J U GuttermanE M Hersh
Nov 1, 1967·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D CrowtherR I Sewell
Sep 1, 1970·Cellular Immunology·P Perlmann, H Perlmann
Mar 1, 1971·American Journal of Clinical Pathology·L T YamW H Crosby

❮ Previous
Next ❯

Citations

Jan 1, 1982·Leukemia Research·E M HershJ Morgan
Mar 1, 1983·Clinical Immunology and Immunopathology·P H de MulderC Haanen
Jan 1, 1984·European Journal of Cancer & Clinical Oncology·R J ten BergeP F Bruning
Oct 1, 1986·The British Journal of Surgery·J R MonsonP J Guillou
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C F VerschraegenM A Burgess

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.